ATE326524T1 - Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut - Google Patents

Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut

Info

Publication number
ATE326524T1
ATE326524T1 AT98934131T AT98934131T ATE326524T1 AT E326524 T1 ATE326524 T1 AT E326524T1 AT 98934131 T AT98934131 T AT 98934131T AT 98934131 T AT98934131 T AT 98934131T AT E326524 T1 ATE326524 T1 AT E326524T1
Authority
AT
Austria
Prior art keywords
fibrinogen
lactobacillus
blood
content
reduce
Prior art date
Application number
AT98934131T
Other languages
English (en)
Inventor
Hanna Bukowska
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Application granted granted Critical
Publication of ATE326524T1 publication Critical patent/ATE326524T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/856—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98934131T 1997-08-05 1998-07-30 Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut ATE326524T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702860A SE510753C2 (sv) 1997-08-05 1997-08-05 Användning av en stam av Lactobacillus för tillverkning av ett läkemedel för reduktion av fibrinogenhalten i blod

Publications (1)

Publication Number Publication Date
ATE326524T1 true ATE326524T1 (de) 2006-06-15

Family

ID=20407874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98934131T ATE326524T1 (de) 1997-08-05 1998-07-30 Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut

Country Status (19)

Country Link
US (1) US6214336B1 (de)
EP (1) EP0990024B1 (de)
JP (1) JP4651814B2 (de)
KR (1) KR100517755B1 (de)
CN (1) CN1142995C (de)
AR (1) AR016798A1 (de)
AT (1) ATE326524T1 (de)
AU (1) AU729413B2 (de)
BR (1) BR9811825A (de)
CA (1) CA2297023C (de)
DE (1) DE69834560T2 (de)
ES (1) ES2259457T3 (de)
IL (1) IL134113A0 (de)
NO (1) NO324881B1 (de)
NZ (1) NZ502610A (de)
PL (1) PL194697B1 (de)
SE (1) SE510753C2 (de)
WO (1) WO1999007827A1 (de)
ZA (1) ZA986769B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU764011B2 (en) 1998-10-01 2003-08-07 Probi Ab Reduction of oxidative stress factors
JP4193269B2 (ja) * 1999-03-04 2008-12-10 ビーエイチピーエイチ カンパニーリミテッド 新規な生体浄化活性型乳酸菌製剤
SE523771C2 (sv) * 1999-05-21 2004-05-18 Probi Ab Sportdryck innehållande mikronäringsämnen i kombination med levande laktobaciller
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
KR20030033950A (ko) * 2001-10-20 2003-05-01 주식회사 알엔에이 유산균 세포질 분획물 또는 유산균 파쇄물을 유효성분으로포함하는 동맥경화 억제제
FR2831395B1 (fr) * 2001-10-25 2004-06-11 Triballat Laiteries Procede de fabrication de produits fermentes a base de soja, produits fermentes obtenus par ce procede et ferments correspondants
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
CN1207382C (zh) * 2003-04-11 2005-06-22 上海光明乳业股份有限公司 植物乳杆菌st－iii菌株及其在调节血脂方面的应用
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
GB0424552D0 (en) * 2004-11-05 2004-12-08 Cambridge Theranostics Ltd Methods and means
AU2006253006B8 (en) 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100909586B1 (ko) * 2007-06-01 2009-07-27 신현길 혈중 콜레스테롤 농도 저하에 효과적인 유산균 및 이들의혼합균주
SE532899C2 (sv) * 2007-06-08 2010-05-04 Probi Ab Förfarande genom fermentering med Lactobacillus plantarum för tillhandahållande av en insulinsvarsreducerande produkt och dess användning farmaceutiskt eller i livsmedel
JP5469873B2 (ja) * 2008-03-11 2014-04-16 株式会社日立製作所 回転電機
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
JP5140791B2 (ja) * 2008-11-27 2013-02-13 森下仁丹株式会社 乳酸菌含有血中ホモシステイン低減剤
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
ES2729765T3 (es) * 2009-06-19 2019-11-06 Dupont Nutrition Biosci Aps Bifidobacterias para el tratamiento de la insuficiencia cardíaca congestiva
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
CN102031229B (zh) * 2009-09-24 2012-05-30 家医国际生化股份有限公司 具有肠胃道吸附能力及排除胆固醇能力的植物乳杆菌
PL2521769T3 (pl) * 2010-01-08 2017-01-31 Gervais Danone Sa Pałeczki kwasu mlekowego z działaniem przeciwutleniającym
GB201319540D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201319538D0 (en) 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
CN110786435B (zh) * 2019-11-19 2022-08-23 四川农业大学 产高活性纤溶酶原激活剂的植物乳杆菌及用其发酵的果蔬汁饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0647551B2 (ja) * 1986-12-01 1994-06-22 株式会社ヤクルト本社 血圧降下剤
JP2676250B2 (ja) * 1989-03-20 1997-11-12 株式会社ヤクルト本社 血圧降下剤およびその製造法
JP2855290B2 (ja) * 1990-11-30 1999-02-10 株式会社ヤクルト本社 脂質代謝改善剤
JPH04264034A (ja) * 1991-02-18 1992-09-18 Snow Brand Milk Prod Co Ltd 生体内過酸化脂質抑制剤
JPH0525055A (ja) * 1991-07-22 1993-02-02 Yakult Honsha Co Ltd 血圧降下剤
SE469875C (sv) * 1991-07-25 1997-02-05 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
JPH06116155A (ja) * 1992-10-08 1994-04-26 Yakult Honsha Co Ltd 血清コレステロール低下剤
JP2801479B2 (ja) * 1992-10-09 1998-09-21 株式会社トクヤマ 補綴材料の製造方法
JP2992945B2 (ja) * 1994-03-11 1999-12-20 カルピス株式会社 ラクトバチルス・アシドフィルス乳酸菌
JPH08208512A (ja) * 1995-02-03 1996-08-13 Nippon Chem Res Kk 血栓形成阻害剤

Also Published As

Publication number Publication date
IL134113A0 (en) 2001-04-30
DE69834560T2 (de) 2006-11-02
JP4651814B2 (ja) 2011-03-16
EP0990024A1 (de) 2000-04-05
AU8372698A (en) 1999-03-01
SE510753C2 (sv) 1999-06-21
NO20000268L (no) 2000-01-19
EP0990024B1 (de) 2006-05-17
AR016798A1 (es) 2001-08-01
DE69834560D1 (de) 2006-06-22
KR20010022617A (ko) 2001-03-26
US6214336B1 (en) 2001-04-10
BR9811825A (pt) 2000-08-15
CN1142995C (zh) 2004-03-24
JP2001512747A (ja) 2001-08-28
ES2259457T3 (es) 2006-10-01
NO20000268D0 (no) 2000-01-19
CN1265141A (zh) 2000-08-30
NO324881B1 (no) 2007-12-27
NZ502610A (en) 2000-12-22
SE9702860D0 (sv) 1997-08-05
CA2297023C (en) 2010-03-30
PL194697B1 (pl) 2007-06-29
AU729413B2 (en) 2001-02-01
WO1999007827A1 (en) 1999-02-18
ZA986769B (en) 1999-02-02
CA2297023A1 (en) 1999-02-18
KR100517755B1 (ko) 2005-09-30
SE9702860L (sv) 1999-02-06
PL338578A1 (en) 2000-11-06

Similar Documents

Publication Publication Date Title
ATE326524T1 (de) Verwendung von lactobacillus zur verminderung des fibrinogengehalts im blut
DE852949T1 (de) Verwendung von Alpha-Aminosäuren zur Förderung des desmosomalen Abbaues oder der Abschuppung der Hornschicht
DE69830660D1 (de) Behandlung von atemstillstand im schlaf
DE69712003D1 (de) Modifikation von xylanase zur Verbesserung von Thermophilicität, alkophilicität und thermostabilität
DE69530284T2 (de) Nicht-invasive nicht-spectrophotometrische infrarotmessung der konzentration von substanzen im blut
DE3482625D1 (de) Probenahme und bestimmung von okkultem blut in derselben.
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE69727332D1 (de) Zubereitungen enthaltend Kollagen, Vitamin D3 und Kalzium zur Verstärkung des Knochens
DE69700813T2 (de) Verwendung von stabilen aminofunktionellen latexen in wässrigen tinten
DE69724110D1 (de) Absorbierender Wegwerfartikel mit geringem Feuchtigkeitsgehalt
NZ215660A (en) Tissue plasminogen activator modified in the growth factor domain
DE69813935D1 (de) Verwendung von Retinoiden zur Induzierung von Hautpigmentierung
DE69713312D1 (de) Verwendung von arabinogalaktan in kryokonservierungsmedien für zelle
DE69517836T2 (de) Proteinhaltiges Mittel zur Verbesserung der Geschmacksqualität von Lebensmitteln
DE69535031D1 (de) Selektive Acylierung von Epsilon-Aminogruppen in Insulin
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69827245D1 (de) Ohrteil zur unterdrückung von lärm
ATE501640T1 (de) Inkorporation von exogenen milchsäurebakterien in die mikroflora
DE69800581T2 (de) Reagens zur Bestimmung von Leukocyten- und Hämoglobin-Konzentration in Blut
DE3873945D1 (de) Verwendung von polyglutaminsaeure in nahrungsmitteln.
DE58901722D1 (de) Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen.
DE69431590T2 (de) In der anaerobischen bestimmung von analyten verwendbare zusammensetzungen
DE69512674T2 (de) Konversion von nylon und/oder nylon 6,6 zur adipinsäure
DE69730451D1 (de) Kassette zur aufnahme von flachen artikeln
ID19618A (id) Komposisi komposisi asam amino dan pemakaiannya dalam makanan untuk pengobatan

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties